Trial of amifostine in autologous stem cell transplant.
Sastry
P
P
Bhagwat
R
R
Biswas
G
G
Khadwal
A
A
Narayanan
P
P
Bakshi
A
A
Parikh
P
P
D000293:Adolescent; D000328:Adult; D004999:Amifostine / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D006689:Hodgkin Disease / Q000097:blood / Q000150:complications / Q000628:therapy*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000628:therapy*; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000009:adverse effects; D011837:Radiation-Protective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
D011837:Radiation-Protective Agents; D003561:Cytarabine; D011034:Podophyllotoxin; D004999:Amifostine; D008558:Melphalan; D002330:Carmustine